Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 in Moderately to Severely Active Crohn's Disease
NCT06233461Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in Crohn's disease (4 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants With Endoscopic Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) at 12 weeks. Started Mar 2024; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06233461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233461.